Session Information
Date: Monday, June 20, 2016
Session Title: Parkinson's disease: Non-motor symptoms
Session Time: 12:30pm-2:00pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: The aim of this study was to investigate effects of dophaminergic therapy on olfaction of patients with Parkinson’s disease.
Background: Influence of dopaminergic drugs on non-motor symptoms of Parkinson’s disease has received little attention. Olfactory function is known to be influenced by a number of factors – smoking, hormonal changes, age, neurodegenerative processes etc. Several studies have found that without a motor symptom of Parkinson’s disease – olfactory dysfunction is not dependent on the use of specific therapy.
Methods: Total of 52 patients with Parkinson’s disease were included in the study and were divided into three groups comparable in age, sex and disease characteristics. First group consisted of 12 patients with newly diagnosed Parkinson’s disease (patients not received treatment), the second group – of 20 patients receiving Levodopa combination treatment, the third group included 20 patients receiving dopamine receptor agonists in combination with amantadine. Olfactory function was tested in all patients using Sniffing Sticks Test. Performance was calculated as a summary of points earned for all of three subtests. The result (Threshold, Discrimination and Identification – TDI-point) of 30 and higher was considered normosmia, 30-15 points – hyposmia, result less than 15 points indicated functional anosmia.
Results: All patients demonstrated olfactory dysfunction of varying degree: 50 patients (96,2%) were diagnosed with hyposmia, 1 patient (1,9%) had anosmia and 1 patient didn’t have any olfactory dysfunction. No significant differences in test results were found between groups (TDI – 18,4±3,2 points in I group, TDI – 18,8±3,5 points in II group and TDI – 18,7±3,6 points in III group).
Conclusions: Olfactory dysfunction of patients with Parkinson’s disease present at the onset of motor manifestations and is not influenced by dophaminergic therapy.
To cite this abstract in AMA style:
O. Izhboldina, I. Zhukova, N. Zhukova, V. Alifirova, A. Latypova, M. Nikitina, Y. Mironova. Dophaminergic therapy and its influence on the olfactory function of patients with Parkinson’s disease [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/dophaminergic-therapy-and-its-influence-on-the-olfactory-function-of-patients-with-parkinsons-disease/. Accessed June 15, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/dophaminergic-therapy-and-its-influence-on-the-olfactory-function-of-patients-with-parkinsons-disease/